abciximab (Reopro)
abciximab is an FDA-licensed reference biologic from Janssen Biotech, Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
1994
Reference approved
Reference product
Reopro abciximab
Janssen Biotech, Inc.
- Approved
- Dec 22, 1994
- Marketing
- Disc
- Center
- CDER
- Patents
- None listed
Molecular structure
Experimental 3D structure for abciximab from the RCSB Protein Data Bank (PDB 6V4P).
Interactive biological assembly from PDB entry 6V4P. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here — no need to leave the page.
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for abciximab, in chronological order.
Reference approval
Approval date of the reference abciximab product.
32 yr ago
Frequently asked questions
Are there biosimilars approved for abciximab (Reopro)?
No 351(k) biosimilars or interchangeable biosimilars referencing abciximab are listed in the FDA Purple Book yet.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsThe list of FDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 & Inspection DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.